Sjögren’s has no FDA-approved medicines. Amgen’s study drug lowered disease activity in Phase 3.
Amgen's Phase 3 study of dazodalibep in Sjögren's disease showed significant reductions in systemic disease activity and patient-reported dryness. The trial met primary and secondary endpoints, with statistically meaningful improvements compared to placebo. Amgen also presented data on UPLIZNA, KRYSTEXXA, and TAVNEOS at ACR Convergence 2026.
How this was made
The 30-second read
Why it matters
The data could accelerate FDA discussions and increase investor optimism for a first approved therapy in Sjögren's disease.
Market read
First‑in‑class trial success may drive Amgen's share price and influence the broader biotech sector.
What to watch
Potential safety concerns, competition from other CD40L antagonists, and the need for larger Phase 3 confirmatory studies.
Background
Amgen presented late‑breaking Phase 3 results at the ACR Convergence 2026 meeting, emphasizing its pipeline in rare autoimmune diseases.
Ticker impact
Amgen reported positive Phase 3 OASIZ-301 trial results for dazodalibep in Sjögren's disease, showing statistically significant reductions in disease activity versus placebo.
likely upward pressure as the market prices in the successful trial outcome
Phase 3 data is a primary disclosure for a biotech; such results historically move share prices, especially for an unmet‑need indication.
Market effects
Strengthens the autoimmune/rare‑disease biotech sector and may lift peers with similar pipelines.
U.S. biotech market may see modest gains; limited immediate impact on broader indices.
Highlights continued innovation in rare disease therapeutics, relevant to global investors tracking biotech pipelines.
Counterpoint
If the trial data fails to translate into regulatory approval or commercial uptake, the stock could face disappointment.
Key entities
- companyAmgen
US‑listed biotech developing dazodalibep.
- drugDazodalibep
CD40L antagonist under Phase 3 evaluation for Sjögren's disease.
